Syndax Pharmaceuticals Inc 8-K

What Happened
Syndax Pharmaceuticals filed an 8-K on June 4, 2026 announcing a privately negotiated sale of $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031. The Notes will be issued under an indenture with U.S. Bank Trust Company, N.A. as trustee and the private placement is expected to close on June 10, 2026. Interest accrues at 2.25% per year, payable semiannually beginning December 15, 2026. The Company expects net proceeds of approximately $243 million to be used for general corporate purposes, including working capital, R&D, commercialization and business development.

Key Details

• Principal amount: $250.0 million of 2.25% Convertible Senior Notes due June 15, 2031; expected closing June 10, 2026.
• Conversion terms: initial conversion rate of 40.3894 shares per $1,000 principal (≈ $24.76 per share), a ~35% premium to the June 3, 2026 closing stock price. Conversion may occur upon specified triggers and freely (subject to timing limits) after March 15, 2031.
• Redemption/repurchase: Company may not redeem notes before June 20, 2029; may redeem after that date if stock trades ≥130% of the conversion price for specified periods. Noteholders may require repurchase at 100% of principal on certain “fundamental change” events.
• Proceeds & use: estimated net proceeds ≈ $243M after fees; intended for working capital, research & development, commercialization and business development.

Why It Matters
This transaction adds $250M of senior unsecured convertible debt to Syndax’s balance sheet while providing roughly $243M in cash to fund operations and growth initiatives. The low 2.25% coupon limits near-term cash interest expense, but conversion could dilute existing shareholders if the stock rises to the applicable conversion thresholds (initial conversion price ≈ $24.76). Investors should watch the conversion triggers, potential future dilution, the redemption window beginning in 2029, and customary default provisions that could accelerate repayment in certain events. The company also issued a press release on June 4, 2026 announcing the pricing.